

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

**POLL RESULTS OF SPECIAL GENERAL MEETING
HELD ON 1 SEPTEMBER 2026**

References are made to the circular (the “**Circular**”) and the notice of the SGM (the “**Notice**”) of Kaisa Health Group Holdings Limited (the “**Company**”) both dated 13 August 2026 regarding the revised proposal on change of company name. Unless the context otherwise required, capitalised terms used in this announcement shall have the same meanings as defined in the Circular.

POLL RESULTS OF THE SGM

Pursuant to Rule 13.39(4) of the Listing Rules and the bye-laws of the Company, the voting of the special resolution proposed (the “**Proposed Resolution**”) at the SGM of the Company held on 1 September 2026 was taken by poll.

The Company is pleased to announce that the Proposed Resolution was duly passed by the Shareholders at the SGM. The poll results are as follows:

Special Resolution <i>(Note)</i>	Number of Votes (%)	
	For	Against
To approve the change of the English name of the Company from “Kaisa Health Group Holdings Limited” to “Qinghai Biotech Pharmaceutical Group Limited” and the adoption of the Chinese name “青海生物製藥集團有限公司” as the secondary name of the Company in place of the current secondary name “佳兆業健康集團控股有限公司”.	52,303,632 (100%)	0 (0%)

Note:

For the full text and details of the Proposed Resolution, please refer to the Notice and the Circular.

As more than 75% of the votes were cast in favour of the Proposed Resolution, it was duly passed as a special resolution of the Company at the SGM.

As at the date of the SGM, the issued and fully paid-up share capital of the Company comprised 103,632,754 Shares, which was the total number of Shares entitling the holders to attend and vote on the Proposed Resolution at the SGM and the Company did not hold any treasury shares, including any treasury shares held in or deposited with the Central Clearing and Settlement System.

There were no Shares entitling the holders thereof to attend and abstain from voting in favour of the Proposed Resolution as set out in Rule 13.40 of the Listing Rules at the SGM, and none of the Shareholders was required under the Listing Rules to abstain from voting at the SGM or had stated their intention in the Circular to vote against or to abstain from voting on the Proposed Resolution at the SGM.

The Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed and acted as the scrutineer for the vote-taking at the SGM.

All the Directors attended the SGM either in person or by telephone conference.

By order of the Board
Kaisa Health Group Holdings Limited
Kwok Ying Shing
Chairman and Executive Director

Hong Kong, 1 September 2026

As at the date of this announcement, the Board comprises six executive Directors, namely Mr. Kwok Ying Shing (Chairman), Mr. Luo Jun, Ms. Luo Tingting, Mr. Xie Binhong, Mr. Yang Feng and Mr. Ye Haoda and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Zhiying.